UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

MARK ONE

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the Quarterly Period ended June 30, 20222023; or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from ________ to ________

 

WORLD HEALTH ENERGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 59-2762023
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

1825 NW Corporate Blvd. Suite 110, Boca Raton, FL 33431
(Address of principal executive offices) Zip Code

 

(561) 870-0440

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 22, 2022,14, 2023, there were issued and outstanding 503,002,741,330520,796,074,663 shares of the registrant’s common stock, par value $0.00001 per share, were outstanding.

 

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

Form 10-Q

June 30, 20222023

 

 Page
  
PART I — FINANCIAL INFORMATION 
  
Item 1 – Financial Statements – Unaudited3
  
Condensed Consolidated Balance Sheets – June 30, 20222023 and December 31, 2021202234
  
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 20222023 and 2021202245
  
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and six months ended June 30, 20222023 and 2021202256
  
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 20222023 and 2021202268
  
Notes to Condensed Consolidated Financial Statements79
  
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations1417
  
Item 3 – Quantitative and Qualitative Disclosures About Market Risk2027
  
Item 4 – Controls and Procedures2027
  
Item 1 – Legal Proceedings2128
  
Item 1A – Risk Factors2128
  
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds2129
  
Item 3 – Defaults upon Senior Securities2229
  
Item 4 – Mine Safety Disclosures2229
  
Item 5 – Other Information2229
  
Item 6 – Exhibits2229
  
Exhibit Index2229
  
SIGNATURES2330

 

i

 

WORLD HEALTH ENERGY HOLDINGS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2023

(UNAUDITED)

2

WORLD HEALTH ENERGY HOLDINGS, INC .

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF JUNE 30, 20222023

IN U.S. DOLLARS

(UNAUDITED)

TABLE OF CONTENTS

Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Interim Condensed Consolidated Balance sheets4
Interim Condensed Consolidated Statements of Comprehensive loss5
Interim Condensed Consolidated Statements of stockholders’ equity6
Interim Condensed Consolidated Statements of cash flows8
Notes to Interim condensed consolidated financial statements9 - 15

 

23

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

 

  June 30,  December 31, 
  2022  2021 
A s s e t s (Unaudited)    
Current Assets        
Cash and cash equivalents  407,979   46,022 
Accounts receivable, net  12,433   10,022 
Payments on account of investment  900,000   900,000 
Other current assets  175,964   356,131 
T o t a l Current assets  1,496,376   1,312,175 
         
Right Of Use asset arising from operating lease  176,328   201,518 
Long term prepaid expenses  22,857   25,723 
Property and Equipment, Net  36,153   27,777 
Funds in respect of employee rights upon termination  20,652   21,182 
         
T o t a l assets  1,752,366   1,588,375 
         
Liabilities and Shareholders’ Deficit        
Current Liabilities        
Accounts payable  92,497   80,059 
Right Of Use liabilities arising from operating lease  42,733   45,756 
Other account liabilities  588,268   638,388 
T o t a l current liabilities  723,498   764,203 
         
Liability for employee rights upon retirement  152,663   157,860 
Long term loan from parent company  2,012,339   2,012,339 
Right Of Use liabilities arising from operating lease  132,026   173,227 
         
T o t a l liabilities  3,020,526   3,107,629 
         
Stockholders’ Deficit        
Preferred stock, par $0.0007, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of June 30, 2022 and December 31, 2021.  3,500   3,500 
Series B Convertible Preferred stock, par $0.0007, 3,870,000 shares authorized, 0 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.  -   - 
Preferred stock, value  3,500   3,500 
Common stock, par $0.00001, 750,000,000,000 shares authorized at June 30, 2022 and December 31, 2021. 493,002,741,330 and 488,499,407,996 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.  66,884,719   66,839,685 
Additional paid-in capital  (57,929,134)  (62,263,494)
Proceeds on account of shares  250,000   - 
Foreign currency translation adjustments  (5,495)  (5,495)
Accumulated deficit  (10,471,750)  (6,093,450)
T o t a l stockholders’ deficit  (1,268,160)  (1,519,254)
T o t a l liabilities and stockholders’ deficit  1,752,366   1,588,375 
  June 30, 2023  December 31, 2022 
  (Unaudited)   (Audited) 
Assets        
Current Assets        
Cash and cash equivalents  267,151   56,346 
Accounts receivable, net  34,413   23,362 
Prepaid share based payment to service providers  -   55,556 
Related party  63,209   50,253 
Other current assets  83,831   90,991 
Total Current assets  448,604   276,508 
         
Non-current assets        
Right of use asset arising from operating lease  142,272   166,882 
Long term prepaid expenses  22,521   23,679 
Property and equipment, net  46,756   43,167 
Funds in respect of employee rights upon termination  28,373   28,824 
Investment in investee (Note 5)  152,766   - 
Intangible assets  9,693,958   9,693,958 
Total non-current assets  10,086,646   9,956,510 
         
Total assets  10,535,250   10,233,018 
         
Liabilities and Shareholders’ Equity        
Current Liabilities        
Accounts payable  135,379   107,979 
Short term operating lease liability  56,432   57,971 
Other current  liabilities  472,830   621,733 
Total current liabilities  664,641   787,683 
         
Non-current Liabilities        
Liability for employee rights upon retirement  196,834   180,066 
Long term loan from parent company  2,012,339   2,012,339 
Long term operating lease liability  69,133   96,102 
Deferred tax liability  872,456   872,456 
Total current liabilities  3,150,762   3,160,963 
         
Total liabilities  3,815,403   3,948,646 
Stockholders’ Equity        
Series A preferred stock, par $0.0007, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of June 30, 2023, and December 31, 2022  3,500   3,500 
Preferred stock, value  3,500   3,500 
Common stock, par $0.00001, 750,000,000,000 shares authorized as of June 30, 2023 and December 31, 2022. 520,796,074,663 and 516,302,741,330 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively  67,162,651   67,117,718 
Additional paid-in capital  (36,194,050)  (40,614,231)
Treasury stock at cost – 20,000,000,000 shares of common stock  (8,000,000)  (8,000,000)
Accumulated other comprehensive loss  (9,095)  (2,611)
Accumulated deficit  (20,027,804)  (16,035,848)
Total Company’s stockholders’ equity  2,935,202   2,468,528 
Non-controlling interests  3,784,645   3,815,844 
Total stockholders’ equity  6,719,847   6,284,372 
Total liabilities and stockholders’ equity  10,535,250   10,233,018 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

34

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

 

 2022 2021 2022 2021  2023  2022  2023  2022 
 Six months ended Three months ended  Six months ended Three months ended 
 June 30 June 30  June 30  June 30 
 2022 2021 2022 2021  2023  2022  2023  2022 
 (Unaudited)  (Unaudited) (Unaudited)  (Unaudited) 
                  
Revenues  43,754   81,450   11,212   48,801   134,986   43,754   102,646   11,212 
                                
Research and development expenses  (243,024)  (253,860)  (119,518)  (81,089)  (1,005,123)  (451,344)  (502,187)  (327,838)
Selling and marketing expenses  (30,197)  -   (3,527)  - 
General and administrative expenses  (270,341)  (269,654)  (147,704)  (145,169)  (3,132,840)  (4,007,344)  (1,148,382)  (2,458,216)
Share based compensation expenses  

(3,945,323

)  -   

(2,518,832

)  - 
Operating loss  (4,414,934)  (442,064)  (2,774,842)  (177,457)  (4,033,174)  (4,414,934)  (1,551,450)  (2,774,842)
Financing income (expenses), net  36,634   (30,916)  33,338   (29,432)
Finance income, net  15,503   36,634   10,614   33,338 
Loss before equity in net loss of equity investments  (4,017,671)  (4,378,300)  (1,540,836)  (2,741,504)
Less: Equity in net gain (loss) of equity investments  (227)  -   250   - 
Net loss  (4,378,300)  (472,980)  (2,741,504)  (206,889)  (4,017,898)  (4,378,300)  (1,540,586)  (2,741,504)
Net loss attributable to non-controlling interests  25,942   -   12,930   - 
Net loss attributable to the Company’s stockholders  (3,991,956)  (4,378,300)  (1,527,656)  (2,741,504)
                                
Basic and diluted net loss per share  (0.00)  (0.00)  (0.00)  (0.00)
Basic net loss per share  (0.00)  (0.00)  (0.00)  (0.00)
                
Weighted average number of shares outstanding used in computing basic and diluted net loss per share  518,062,280,925   490,672,188,843   519,297,869,535   491,853,620,450 
Weighted average number of shares outstanding used in computing basic and diluted net loss per share  518,062,280,925   490,672,188,843   519,297,869,535   491,853,620,450 
                
Comprehensive loss:                
Net loss  (4,017,898)  (4,378,300)  (1,540,586)  (2,741,504)
Other comprehensive loss - Foreign currency translation adjustments  (6,484)  -   (4,211)  - 
Comprehensive loss  (4,378,300)  (472,980)  (2,741,504)  (206,889)  (4,024,382)  (4,378,300)  (1,544,797)  (2,741,504)
                
Loss per share (basic and diluted)  (0.00)  (0.00)  (0.00)  (0.00)
Net - loss attributable to non-controlling interests  25,942   -   12,930   - 
Other comprehensive loss attributable to non-controlling interests  (5,257)  -   (4,041)  - 
Comprehensive loss attributable to the Company’s stockholders  (4,003,697)  (4,378,300)  (1,535,908)  (2,741,504)

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

45

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

 

                                  
  Preferred Stock, $0.0007, Par Value  

Preferred Stock B,

$0.0007, Par Value

  

Common Stock,

$0.0007, Par Value

  Additional paid-in capital  Proceeds on account of shares  

Foreign currency

translation

adjustments

  Accumulated deficit  

Total

Company’s stockholders’ deficit

 
  Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount                
BALANCE AT JANUARY 1, 2022  5,000,000   3,500     -      -   488,499,407,996   66,839,685   (62,263,494)  -   (5,495)  (6,093,450)  (1,519,254)
Issuance of shares  -   -   -   -   2,840,000,000   28,400   255,600   -   -   -   284,000 
Share based payment to service providers  -   -   -   -   -   -   1,310,239   -           1,310,239 
Proceeds on account of shares  -   -   -   -   -   -   -   290,000   -   -   290,000 
Comprehensive loss for three month ended March 31, 2022  -   -   -   -   -   -   -   -   -   (1,636,796)  (1,636,796)
BALANCE AT MARCH 31, 2022 (Unaudited)  5,000,000   3,500   -   -   491,339,407,996   66,868,085   (60,697,655)  290,000   (5,495)  (7,730,246)  (1,271,811)
Issuance of shares  -   -   -   -   1,633,333,334   16,333   310,917   (40,000)  -   -   287,250 
Share based payment to employees and service providers  -   -   -   -   30,000,000   300   2,457,605   -   -   -   2,457,905 
Comprehensive loss for three month ended June 30, 2022  -   -   -   -   -   -   -   -   -   (2,741,504)  (2,741,504)
BALANCE AT JUNE 30, 2022 (Unaudited)  5,000,000   3,500   -   -   493,002,741,330   66,884,719   (57,929,134)  250,000   (5,495)  (10,471,750)  (1,268,160)
  Number of Shares  Amount  Number of
Shares
  Amount  paid-in capital  account of shares  Treasury shares  Comprehensive
Income
 Accumulated
deficit
equity (deficit)  Controlling
Interest
  equity (deficit) 
  Series A Preferred Stock  Common Stock  Additional  Proceeds on     Accumulated Other     Total
Company’s
stockholders
  Non-  Total
stockholders’
 
  Number of Shares  Amount  Number of
Shares
  Amount  paid-in capital  account of shares  Treasury shares  Comprehensive
Income
 Accumulated
deficit
equity (deficit)  Controlling
Interest
  equity (deficit) 
                                     
BALANCE AS OF DECEMBER 31, 2021  5,000,000   3,500   488,499,407,996   66,839,685   (62,263,494)  -    -    (5,495)  (6,093,450)  (1,519,254)        -   (1,519,254)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2022:                                                
Issuance of shares  -   -   2,840,000,000   28,400   255,600       -   -   -   284,000   -   284,000 
Share-based payment to employees and services providers  -   -   -   -   1,310,239       -   -   -   1,310,239   -   1,310,239 
Proceeds on account of shares  -   -   -   -   -   290,000   -   -   -   290,000   -   290,000 
Net loss  -   -   -   -                       (1,636,796)  (1,636,796)  -   (1,636,796)
BALANCE AS OF MARCH 31, 2022  5,000,000   3,500   491,339,407,996   66,868,085   (60,697,655)  290,000   -   (5,495)  (7,730,246)  (1,271,811)  -   (1,271,811)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED JUNE 30, 2022:                                                
Issuance of shares  -   -   1,633,333,334   16,334   310,917  

(40,000

)   -   -   -   287,250   -   287,250 
Share-based payment to employees and services providers  -   -   30,000,000   300   2,457,605   -   -   -   -   2,457,905   -   2,457,905 
Net loss  -   -   -   -                   (2,741,504)  (2,741,504)  -   (2,741,504)
BALANCE AS OF JUNE 30, 2022  5,000,000   3,500   493,002,741,330   66,884,719   (57,929,134)  250,000   -   (5,495)  (10,471,750)  (1,268,160)  -   (1,268,160)

                                
   Preferred Stock, $0.0007, Par Value  Preferred Stock B, $0.0007, Par Value  

Common Stock,

$0.0007, Par Value

  Additional paid-in capital  

Foreign currency

translation

adjustments

  Accumulated deficit  Total Company’s stockholders’ deficit 
   Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount             
BALANCE AT JANUARY 1, 2021   5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,585   (63,339,224)-  (5,495)  (1,496,637)  (1,982,562)
Comprehensive loss for three month ended March 31, 2021   -   -   -   -   -   -   - -  -   (266,091)  (266,091)
BALANCE AT MARCH 31, 2021 (Unaudited)   5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,585   (63,339,224)-  (5,495)  (1,762,728)  (2,248,653)
                                          
Comprehensive loss for three month ended June 30, 2021   -   -   -   -   -   -   - -  -   (206,889)  (206,889)
Comprehensive loss   -   -   -   -   -   -   - -  -   (206,889)  (206,889)
BALANCE AT JUNE 30, 2021 (Unaudited)   5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,585   (63,339,224)-  (5,495)  (1,969,617)  (2,455,542)

The accompanying notes are an integral part of the condensed consolidated financial statement

56

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(U.S. dollars, except share and per share data)

  Series A Preferred Stock  Common Stock  Additional   

Proceeds

on  

     Accumulated Other      

Total
Company’s stockholders

  Non-   Total
stockholders’ 
 
  Number of Shares  Amount  Number of Shares  Amount  paid-in capital  account of shares  Treasury
shares
  Comprehensive Income  Accumulated deficit  equity (deficit)  Controlling Interest  equity (deficit) 
                                     
BALANCE AS OF DECEMBER 31, 2022  5,000,000   3,500   516,302,741,330   67,117,718   (40,614,231)  -   (8,000,000)  (2,611)  (16,035,848)  2,468,528   3,815,844   6,284,372 
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2023:                                                
Issuance of shares  -   -   1,640,000,000   16,400   512,600   -   -   -   -   529,000   -   529,000 
Share-based payment to employees and services providers  -   -   -   -   2,219,109   -   -   -   -   2,219,109   -   2,219,109 
Other comprehensive loss  -   -   -   -   -   -   -   (2,273)      (2,273)  (1,216)  (3,489)
Net loss  -   -   -   -                           (2,464,300)  (2,464,300)  (13,012)  (2,477,312)
BALANCE AS OF MARCH 31, 2023  5,000,000   3,500   517,942,741,330   67,134,118   (37,882,522)  -   (8,000,000)  (4,884)  (18,500,148)  2,750,064   3,801,616   6,551,680 
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED JUNE 30, 2023:                                                
Issuance of shares  -   -   2,083,333,333   20,833   279,167   -   -   -   -   300,000   -   300,000 
Issuance of shares for investment in an investee  -   -   770,000,000   7,700   146,300   -   -   -   -   154,000   -   154,000 
Share-based payment to employees and services providers  -   -   -   -   1,263,005   -   -   -   -   1,263,005   -   1,263,005 
Other comprehensive loss  -   -   -   -   -   -   -   (4,211)      (4,211)  (4,041)  (8,252)
Net loss  -   -   -   -                    (1,527,656)  (1,527,656)  (12,930)  (1,540,586)
BALANCE AS OF JUNE 30, 2023  5,000,000   3,500   520,796,074,663   67,162,651   (36,194,050)  -   (8,000,000)  (9,095)  (20,027,804)  2,935,202   3,784,645   6,719,847 

7

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars except)

 

  2022  2021 
  Six months ended 
  June 30, 
  2022  2021 
  (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period  (4,378,300)  (472,980)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:        
Depreciation and amortization  4,930   3,456 
Increase (decrease) in liability for employee rights upon retirement  (5,197)  26,301 
Share based compensation  3,945,323     
Interest on lease liability  (19,034)  (11,613)
Increase in accounts receivable  (2,411)  (14,951)
Increase in other current assets  8,668   (11,017)
Increase (decrease) in accounts payable  12,438   (3,571)
Increase (decrease) in other accounts liabilities  (50,120)  13,686 
Net cash used in operating activities  (483,703)  (470,689)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Loans received from (granted to) related parties  7,186   (5,226)
Proceeds from related parties  -   (6,515)
Loan to investee company  (10,000)  - 
Increase in asset for employee rights upon retirement  530   - 
Purchase of property and equipment  (13,306)  - 
Net cash provided by (used in) investing activities  (15,590)  (11,741)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from stock issued for cash  611,250   - 
Payments on account of shares  250,000   - 
Loan received from parent company  -   167,736 
Net cash provided by financing activities  861,250   167,736 
         
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  361,957   (314,694)
         
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  46,022   359,949 
         
CASH AND CASH EQUIVALENTS AT END OF PERIOD  407,979   45,255 
         
Supplemental disclosure of cash flow information:        
Non cash transactions:        
Initial recognition of operating lease right-of-use assets  -   242,906 
         
Initial recognition of operating lease liability  -   (242,906)
  2023  2022 
  Six months ended 
  June 30, 
  2023  2022 
  (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period  (4,017,898)  (4,378,300)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:        
Depreciation  8,574   4,930 
Change in liability for employee rights upon retirement  17,219   (4,667)
Equity in losses of non-consolidated entity  227   - 
Share-based compensation expense  3,537,669   3,945,323 
Change in operating lease liability  (3,898)  (19,034)
Change in accounts receivable  (11,051)  (2,411)
Change in other current assets  7,018   8,668
Change in accounts payable  27,399   12,438
Change in other accounts liabilities  (11,939)  (50,120)
Net cash used in operating activities  (446,680)  (483,173)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Loans received from (granted to) related parties  (12,843)  7,186
Loan to investee company      (10,000)
Purchase of property and equipment  (12,163)  (13,306)
Net cash used in investing activities  (25,006)  (16,120)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from issuance of common stock  681,000   611,250 
Proceeds on account of shares  -   250,000 
Net cash provided by financing activities  681,000   861,250 
         
Effect of exchange rate changes on cash and cash equivalents  1,491   - 
         
INCREASE IN CASH AND CASH EQUIVALENTS  210,805  361,957 
         
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  56,346   46,022 
         
CASH AND CASH EQUIVALENTS AT END OF PERIOD  267,151   407,979 

Supplemental disclosure of cash flow information:
Non cash transactions:
Investment in purchase of subsidiary154,000-
Issuance of share in exchange for debt144,000-

 

The accompanying notes are an integral part of the condensed consolidated financial statement

 

68

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 – GENERAL

 

A. Operations

A.Operations

 

World Health Energy Holdings, Inc., (the “Company” or “WHEN”), was formed on May 21, 1986 under the laws of the State of Delaware. The Company has invested in and abandoned a variety of internally developed software programs that it strove to commercialize.

 

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (Hereinafter: “RNA”(“RNA”).

 

RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity relatedcybersecurity-related products.

 

In anticipation of the transaction contemplated under the SG Merger Agreement, SG 77 Inc., a Delaware Corporationcorporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

B.SG Transaction

CrossMobile investment agreement

On April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (“SG Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Sub”), UCG, SG, and RNA. Under the terms of the SG Merger Agreement, R2GA merged with SG, with SG as the surviving corporation and a wholly-owned subsidiary of the Company (“SG Merger”). The SG Merger was effective as of April 27, 2020, whereby SG became a direct and wholly owned subsidiary of the Company and RNA became an indirect wholly owned subsidiary of the Company.

 

As consideration for the SG Merger, the Company issued 3,870,000 Series B convertible preferred stock, par value $0.0007 per share, to UCG. Each share of the Series B convertible preferred stock will automatically convert into 100,000 shares of common stock, par value $0.0007, for an aggregate amount of 387,000,000,000 shares of common stock, upon the filing with the Secretary of State of Delaware of an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of common stock that the Company is authorized to issue from time to time.

On October 7, 2021, and following the approval by the stockholders, the Company increase its authorized shares to 750,000,000,000 (from 110,000,000,000 shares) and changed the par value of the common stock to $0.00001 (from $0.0007) (see Note 10).

Following the effectiveness of the Amendment referred to above, on December 3, 2021, the Company issued 387,000,000,000 shares of common stock to UCG upon the automatic conversion of all 3,870,000 outstanding Series B convertible preferred stock issued in April 2020 in connection with the acquisition of RNA from UCG.

The SG Merger was accounted for as a reverse asset acquisition. Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the SG Merger: (i) SG’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the combined company. As a result of the reverse asset acquisition transaction, the shareholders of SG received the largest ownership interest in the Company, and SG was determined to be the “accounting acquirer” in the a reverse asset acquisition transaction.

As a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction.

9

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

C.CrossMobile Transaction

On March 22, 2022, the Company, CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rozensweig, holdsRosenzweig, held 40.67% 40.67% and Mr. George Baumeohl holdsheld 3.33%3.33,% of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”(“CrossMobile Agreement”) pursuant to which the Company is to purchase 26% 26% of the outstanding common share capitalshares of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000restricted shares of Companythe Company’s common stock (the “Initial Investment”). The preferred share capital of CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile

 

CrossMobile filed an application with the Polish Companies Registrar on June 22, 2022 to increase CrossMobile’s share capital in order to effectuate the issuance to WHEN of the CrossMobile ordinary shares representing 26% of the CrossMobile equity interest to WHEN and to register the issuance to CrossMobile of the 10,000,000,000 WHEN shares in consideration thereof. The Companies Registrar approved the requested actions on July 22, 2022 and published on August 1, 2022. The approval and registration by the Polish Companies Registrar is required under local law for CrossMobile to issue to WHEN the CrossMobile ordinary shares representing 26% of CrossMobile. In anticipation of the approval of the increase in the share capital of CrossMobile, WHEN issued to CrossMobile onOn July 13, 2022, the Company issued 10,000,000,000 WHEN shares. Uponcommon shares with fair value of $4 million to Crossmobile to consummate the registration of the Company shareholdings in CrossMobile the closing of the Initial Investment will be deemed to have occurred.transaction.

 

CrossMobile is a licensed mobile virtual network operator (“MVNO”) in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

 

In addition, through January 22, 2024,under the CrossMobile Agreement, the Company has the option, through January 22, 2024, to purchase additional shares of CrossMobile (“Additional Share Purchase Option”) such that following suchthe additional purchase, the Company shall hold approximately 51%51% of CrossMobile’s outstanding share capitalcommon shares on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.

 

On October 25, 2022, the Company exercised the Additional Share Purchase Option (see Note 1C to the annual financial statements of 2022) and acquired the additional 25% shares of CrossMobile such that following the acquisition, the Company increased its holding from 26% to 51% of CrossMobile’s outstanding common stock on a fully diluted basis. In consideration for the exercise of the Additional Share Purchase Option, the Company issued 10,000,000 common stock on November 28, 2022 to Crossmobile.

The Company concluded that the acquired set of assets held at CrossMobile does not meet the definition of a business as substantially all the fair value of the gross assets is concentrated in the license held by CrossMobile. CrossMobile is at it start up stages and has no substantial operations. The only significant asset is the license which constitute more than 90% of the consideration paid.

The acquisition of the additional 25% constitute an asset acquisition in stages and resulted in obtaining control over all assets of CrossMobile and consolidating CrossMobile as of October 25, 2022.

The Company used the cost accumulation method to determine the cost of the acquisition. The Company used the carrying value of its 26% interest and did not recognize any gain or loss on the interest held at CrossMobile previously.

The consideration for the assets of CrossMobile was made through the issuance of 20,000,000,000 WHEN common shares with total fair value of $8 million ($0.0004 per share) and was issued to CrossMobile and not the shareholders of CrossMobile. Hence, upon obtaining control over all the assets of CrossMobile, the Company has gained control over its own shares held at CrossMobile. Based on the guidance in ASC 810-10-45-5, shares held by a subsidiary would not be considered outstanding and hence, the 20,000,000,000 common shares of the Company held by CrossMobile are presented as treasury shares in the consolidated balance sheet.

The assets acquisition of CrossMobile resulted in 49% noncontrolling interests in CrossMobile. The Company analogized from ASC 805-30-30-1 and added the fair value of the noncontrolling interests to the consideration paid for the assets acquired.

As described above the entire consideration paid by WHEN was with its shares, issued to CrossMobile. Based on the guidance in ASC 810-10-45-5 the shares are not considered outstanding. The Company concluded that the fair value of the consideration paid to be based on the fair value of the noncontrolling interests determined to be $7.9 million.

710

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 1 – GENERAL (continue)

Substantially all the consideration were allocated to the license, in addition to $0.9 million costs incurred in connection of the transaction, and hence the license was recognized at $8.8 million.

In addition, the Company recorded deferred tax liability and corresponding increase of the license value in an amount of $0.872 million, based on ASC 740-10-55-170 that accounts for situations when an asset is acquired outside of a business combination and the tax basis of the asset differs from the amount paid assuming tax basis of $0.

The Company, collectively with SG, RNA and CrossMobile are hereunder referred to as the “Group”.

D.InstaView Transaction

On January 26, 2023, the Company, InstaView Ltd. (“InstaView”) and the shareholder of InstaView entered into an Investment Agreement (the “InstaView Investment Agreement”) pursuant to which the Company purchased 26% of the outstanding common share capital of InstaView on a fully diluted basis, in consideration of the issuance by the Company to InstaView of 770,000,000 restricted   shares of Company common stock. Under the InstaView Investment Agreement, subject to InstaView meeting annual revenues target specified in the Investment Agreement for each of the years ending December 31, 2023, 2024 and 2025, as certified by InstaView and its accountants and verified by the Company, the InstaView shareholder would be entitled to potentially up to an additional 230,000,000 shares of the Company’s common stock over this three year period (“contingent consideration”). As of the date of the transaction and as of the balance sheet date respectively, the Company estimates the fair value of the contingent consideration is zero.

In addition, under the InstaView Investment Agreement, the Company has the option to purchase additional shares of InstaView in each of calendar years 2023, 2024 and 2025, representing, in each such year, respectively, 7%, 8% and 10% of the share capital of InstaView for consideration consisting of, respectively, 207,307,692, 236,923,077 and 296,153,846 additional shares of the Company (“the Purchase Option”).

In connection with the InstaView Investment Agreement, the Company, InstaView and the InstaView shareholder also entered into a shareholders agreement pursuant to which the Company was granted standard preemptive rights, veto rights over certain corporate action by InstaView, restrictions on transfer of shares, rights of first offer and tag along rights. In addition, the InstaView shareholder undertook to not compete with InstaView for so long as he is an InstaView shareholder and for a three year period thereafter.

The Company determined the value of the 770,000,000 restricted shares of Company common stock issued to InstaView based on Company’s share price on the agreement date at $154,000 and recorded an equity investment assets in the balance sheet. As of the date of the transaction, the company allocated a total of $62,083 dollars out of this amount to the Purchase Option. The Purchase Option is presented according to a cost model. See also note 2 below as to Company’s accounting policy related to InstaView transaction.

E.Board and Shareholder Authority for Reverse Stock Split

On May 17, 2023, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each twenty thousand or sixty thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular range for the Reverse Stock Split and no application has been presented to FINRA.

11

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continue)

 

B. Going concern uncertainty

F.Liquidity

 

Since inception, the GroupCompany has devoted substantially all its efforts to research and development. The Group is still in its development stage and the extent of the Group’s future operatingincurred losses and the timing of becoming profitable, if ever, are uncertain. As of June 30, 2022, the Group had $407,979 ofnegative cash and cash equivalents, accumulated deficit of $10,471,750, working capital of $772,878 and net losses of $4,378,300 during the six months ended June 30, 2022.flows from operations. The Company has financed its operations mainly through fundraising from various investors.

 

The Group will needand George Baumeohl, a Company director, have entered into an investment agreement signed on November 1, 2022, where the director has committed to secure additional capitalinvest up to $3,000,000 through August 2025, as needed by the Company through the purchase of shares of the Company’s common stock. As of June 30, 2023 an amount of $625,000 out of the $3,000,000 was invested in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Group on acceptable terms, if at all, and the Group cannot give assurance that it will be successful in securing such additional capital (see Note 3 in respect to subscription agreements signed during 2022).Company. See also note 3c.

 

These conditions raise substantial doubt aboutBased on the Company’s abilityprojected cash flows considering the investment agreement, management is of the opinion that its existing cash will be sufficient to continue to operate asmeet its obligations for a “going concern.” The Company’s ability to continue operating as a going concern is dependent on several factors, among them isperiod longer than 12 months from the ability to raise sufficient additional funding.date of the approval of these consolidated financial statements..  

 

The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

C. Risk factors

G.Risk factors

 

The Group face a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.

D. COVID-19

The COVID-19 pandemic continues to create business and economic uncertainty and volatility in the global markets. Many countries around the world are experiencing further outbreaks of the pandemic, following which governments are once again imposing various restrictions. At the same time, there is a recovery trend in the volume of economic activity around the world that leads on one hand, to significant demand for certain products and services and on the other hand, disruptions to worldwide supply chain routes and some raw materials. The Group continues to take measures to ensure the health and safety of its employees, suppliers, other business partners and the communities in which it operates in order to ensure, among others, the operation level, the proper functioning of its facilities and to minimize the pandemic’s potential impact on its business. Manufacturing continues at the Group’s sites without interruptions. However, there is still a difficulty in assessing the future impacts of the pandemic on the Group’s operations, inter alia, in light of the uncertainty of its duration, the extent of its intensity and effects on global supply chains and global markets, and additional countermeasures that may be taken by governments and central banks.

8

WORLD HEALTH ENERGY HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Unaudited  Interim Financial Statements

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the six-months ended June 30, 2022.2023. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2022.2023. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

 

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, Alternative Reporting System, for the year ended December 31, 2022.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.

12

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the going concern assumptions and share based compensation.

9

WORLD HEALTH ENERGY HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

Recent Accounting PronouncementsInvestment in investee

In August 2020,The Company accounts of its options in InstaView in accordance with ASC 321, Investments – Equity Securities. The Company elected the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversionmeasurement alternative under which the options are measured at cost as they have no readily determinable fair value. The carrying amount of the investment is included within Investment in investee, non-current assets in the Consolidated Balance Sheets. The equity securities will be carried at cost less impairment, if any, and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contractssubsequently measured to fair value upon observable price changes in an Entity’s Own Equity” (“ASU 2020-06”). The guidance in ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU 2020-06 also simplify the guidance in ASC Subtopic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The amendments in ASU 2020-06 are effectiveorderly transaction for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted. The guidance must be adopted asidentical or similar investments with any gains or losses recorded to the consolidated statement of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this new guidance, but does not expect it to have a material impact on its financial statements.operations and comprehensive income

 

NOTE 3 – COMMON STOCK

 

a.On February 8, 2023, the Company entered into an investment agreement with a shareholder pursuant to which it raised $60,000 from the private placement of share of our common stock at a per share purchase price of $0.0003, in respect of which it issued to the shareholder to 200,000,000 shares of Common Stock.

Between August and October 2021, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities (the 2021 Private Placements”) where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. Subscription agreements for an aggregate of $900,000 provide that the investors are to remit the subscription proceeds at the time of investment and in three month intervals thereafter, in each case in amounts equal to 20% of their committed amounts. During the six months ended June 30, 2022, the Company received a total of $151,250 on account of these subscription and in consideration thereof issued 1,140,000,000 shares of Common Stock and warrants for an additional 1,140,000,000 shares of Common Stock and the balance is presented as proceeds on account of shares.

b.On February 8, 2023, the Company issued to the investor specified in item 2 above and a designee an aggregate of 1,440,000,000 shares of common stock in satisfaction of a loan made by the shareholder to the Company in the principal amount of $120,000 plus interest of $24,000 of accrued interest, originally received for a period of 10-year.

c.On May 5, 2023 and on June 30, 2023, the Company issued to George Baumeohll, a director and a shareholder, an aggerate of 2,083,333,333 shares of common stock for aggregate subscription proceeds of $625,000   under the November 1, 2022, investment agreement with Mr. Baumeohll in respect of which he is entitled to shares of the Company’s common stock, at a per share price of $0.0003.

d.On May 15, 2023, the Company issued 770,000,000 shares of common stock as consideration under InstaView Transaction (see note 1D above).

 

During the six months ended June 30, 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. As part of the subscription agreements, CrossMobile undertook to issue the investors up to 5% of the issued and outstanding share capital of CrossMobile. During the six months ended June 30, 2022, the Company received a total of $500,000 on account of these subscription and in consideration thereof issued 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock and the balance is presented as proceeds on account of shares.

In May 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities (the May 2022 Private Placements”) in an aggregated amount of $250,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock for a one year period at a per share exercise price of $0.0006. The price per unit is $0.0003. In consideration thereof, the Company issued 833,333,334 shares of Common Stock and warrants for an additional 833,333,334 shares of Common Stock.

On May 19, 2022 the Company issued 30,000,000 share of the Company’s Common Stock to a service provider in exchange for certain tax services. The Company estimated the value of the shares issued at $9,000 based on the share price of the Company as of the issuance date.

1013

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 4 - STOCK OPTIONS

 

On June 21, 2021, the board of directors of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which the Company may issue awards, from time to time, consisting of non-qualified stock options, restricted stock grants and restricted stock units. In addition, stock option awards that qualify under Section 102 of the Israeli Tax Ordinance (New Version) 1961 (the “ITO”), and/or under Section 3(i) of the ITO, may be granted.

Mr. Tromer, the CEO of CrossMobile, was appointed to the Company’s advisory board in February 2022. In connection with his service on the advisory board, on February 14, 2022, he was awarded options under the Company’s 2021 Equity Incentive Plan to purchase 6,000,000,000 shares of the Company’s common stock, at a per share exercise price of $0.0001 per share, which the exercise price for all grants to date to member of the Company’s advisory board. Mr. Tromer’s options vest as follows: 25% (i.e., 1,500,000,000) option shares vest on the first anniversary of the appointment to the advisory board and the balance in increments of 400,000,000 shares on each subsequent three (3) month anniversary.

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.85%, a volatility factor of 397%, dividend yields of 0% and an expected life of 6.25 years and was estimated at $2,400,000.

On January 1, 2022, the Company granted options to purchase 400,000,000 shares of the Company’s Common Stock to a member of its advisory board, under the Company’s 2021 Plan. Options to purchase 100,000,000 shares of Common Stock shall vest on the first anniversary of the agreement and the remaining options shall vest quarterly, over additional 3 years

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.12%, a volatility factor between 391%, dividend yields of 0% and an expected life of 6.25 years and was estimated at $200,000.

On May 15, 2022, the Company granted options under the 2021 Plan (2021) to directors, employees and service providers to purchase an aggregate of 34,900,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0001. Of the options granted, 5,000,000,000 were issued to CEO. The options vest on an annual basis with 25% of the option grant vesting on each anniversary of the option grant. Following vesting the options are exercisable through the sixth month anniversary following the last instalment vesting date.

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 2.84%, a volatility factor of 305.1%, dividend yields of 0% and an expected life of 6.25 years and was estimated at $13,959,141.

111.The following table presents the Company’s stock option activity during the three and six months ended June 30, 2023:

WORLD HEALTH ENERGY HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

The following table presents the Company’s stock option activity during the six months ended June 30, 2022:

SCHEDULE OF STOCK OPTION ACTIVITY

 Number of Options 

Weighted Average

Exercise Price

  Number of
Options
 Weighted
Average
Exercise Price
 
Outstanding at December 31,2021  6,800,000,000   0.0001 
Outstanding at December 31,2022  46,600,000,000   0.001 
Granted  6,400,000,000   0.0001   2,000,000   0.001 
Exercised  -   -   -   - 
Forfeited or expired  -   -   -   - 
Outstanding at March 31,2022  13,200,000,000   0.0001 
Outstanding at March 31,2023  46,602,000,000   0.001 
Granted  34,900,000,000   0.0001   -   - 
Exercised  -   -   -   - 
Forfeited or expired  -   -   -   - 
Outstanding at June 30,2022  48,100,000,000   0.0001 
Number of options exercisable at June 30, 2022  3,541,666,667   0.0001 
Outstanding at June 30,2023  46,602,000,000   0.001 
Number of options exercisable at June 30, 2023  9,600,000,000   0.001 

 

The aggregate intrinsic value of the awards outstanding as of June 30, 20222023 is 19,240,0000. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.00050.0001 as of June 30, 2022,2023, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

The stock options outstanding as of June 30, 2022,2023, have been separated into exercise prices, as follows:

SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE

Exercise price Stock options outstanding Weighted average remaining contractual life – years Stock options vested  Stock options
outstanding
 Weighted average
remaining contractual
life – years
 Stock options
vested
 
  As of June 30, 2022   As of June 30, 2023 
0.0001   48,100,000,000   3.72   3,541,666,667 
0.001   46,602,000,000   3.26   17,525,000,000 
   48,100,000,000   3.72   3,541,666,667    46,602,000,000   3.26   17,525,000,000 

 

The stock options outstanding as of December 31, 2021,June 30, 2022, have been separated into exercise prices, as follows:

 

Exercise price Stock options outstanding Weighted average remaining contractual life – years Stock options vested  Stock options
outstanding
 Weighted average
remaining contractual
life – years
 Stock options
vested
 
  As of December 31, 2021   As of June 30, 2022 
0.0001   6,800,000,000   3.49   - 
0.001   13,200,000,000   3.55   - 
   6,800,000,000   3.49     -    13,200,000,000   3.55   - 

 

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the period of six months ended June 30, 20222023 was $3,759,1443,537,670 and are included in General and Administrative expenses in the Statements of Operations.

 

2.On January 26, 2023, RNA entered into two consulting agreements for the design of new generation of Internet Of Things (“IOT”) devices and for research and update of international needs of IOT devices with two consultants under which it undertook to issue to each of the consultant Non-Plan option to purchase 1,000,000,000 shares of the Company’s common stock at per share exercise price of $0.0002, exercisable over 4 years, of which options for 250,000,000 of the share will vest on each of the anniversaries of the execution of the agreement, beginning with January 24, 2024 and thereafter on each subsequent anniversary, subject to continued services with RNA. The fair value of both of the options was determined using the Black-Scholes pricing model at $563,230, assuming a risk free rate of 3.72%, a volatility factor of 186.71%, dividend yields of 0% and an expected life of 4 years. Total compensation expenses during the six months ended June 30, 2023 amounted to $110,006 and were recorded as share based compensation under research and development expenses.

1214

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 5 - EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES

The Company applies the equity method to investments when it has an ability to exercise significant influence over the operational decision-making authority and financial policies of the investee. During the six months ended June 30, 2023, the Company accounted for its 26% investments in InstaView as equity method investment from January 26, 2023.

The following tables summarize the carrying amounts, including changes therein, of our equity method investment in InstaView during the period:

SCHEDULE OF EQUITY METHOD INVESTMENT

  Six months ended June 30, 2023 
    
Opening balance $- 
Equity investment  91,917 
Other comprehensive loss  (1,007)
Equity losses  (227)
Investments under equity method.  90,683 
Purchased Option  62,083 
Investment in investee as of June 30, 2023 $152,766 

15

NOTE 6 RELATED PARTIES

A. Transactions and balances with related parties

SCHEDULE OF RELATED PARTY EXPENSES 

A.Transactions and balances with related parties

  2023  2022  2023  2022 
  

Six months ended

June 30

  

Three months ended

June 30

 
  2023  2022  2023  2022 
  (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) 
             
General and administrative expenses:                
Salaries and fees to officers  1,420,162   2,028,654   613,219   1,067,882 
(*) of which share based compensation  1,329,597   1,943,090   573,520   1,023,625 
                 
Research and development expenses:                
Salaries and fees to officers  137,213   69,723   59,402   46,308 
(*) of which share based compensation  91,483   26,040   39,504   26,040 

  2022  2021  2022  2021 
  

Six months ended

June 30

  

Three months ended

June 30

 
  2022  2021  2022  2021 
             
General and administrative expenses:                
Salaries and fees to officers  2,028,654   58,793   1,067,882   19,380 
(*) of which share based compensation  1,943,090   -   1,023,625   - 
Share based compensation  1,943,090   -   1,023,625   - 
                 
Research and development expenses:                
Salaries and fees to officers  69,723   40,321   46,308   17,668 
(*) of which share based compensation  26,040   -   26,040   - 
Share based compensation  26,040   -   26,040   - 

B.Balances with related parties and officers:

 

B. Balances with related parties and officers:

  As of June 30,  As of December 31, 
  2022  2021 
       
Other current assets  -   7,186 
Other accounts liabilities  120,000   120,000 
Liability for employee rights upon retirement  167,731   213,371 
Long term loan from related party  2,012,339   2,012,339 

  

 

As of June 30,

  As of December 31, 
  2023  2022 
   (Unaudited)   (Audited) 
         
Other current assets  63,209   50,253 
Other accounts liabilities  103,311   - 
Liability for employee rights upon retirement  123,723   229,167 
Long term loan from related party (*)  2,012,339   2,012,339 

 

NOTE 6 – SUBSEQUENT EVENTS

(*)Received from UCG by December 31, 2021. The loan bears no interest.

 

On July 13, 2022 the Company issued 10,000,000,000 restricted shares of Company common stock to CrossMobile, pending the receipt of the approval of the Polish company registrar to increase the share capital of the CrossMobile and register the CrossMobile ordinary shares issuable to the Company (representing the initial 26% equity stake in CrossMobile), as detailed in note 1 above.

On August 10, 2022, the Company entered into follow on agreement with a consultant providing investor relations services since November 2021 pursuant to which the Company undertook to issue to the Consultant an additional 300 million shares of restricted stock.

1316

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended December 31, 20212022 as filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2022.17, 2023. Certain statements made in this discussion are “forward-looking statements” within the meaning of the private securities litigation reform act of 1995,. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations and the effects that the COVID-19 outbreak, or similar pandemics, could have on our business.operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

General Overview

World Health Energy Holdings Inc. (“we” “us” “our”WHEN” or the “Company” or “WHEN”“us” ) WHEN is a diversified energy, health, andprimarily engaged in the cybersecurity technology company.field. On April 27, 2020, WHEN completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”)Agreement among the Company, R2GA, Inc., a Delaware corporationUCG, SG, and a wholly owned subsidiary of the Company (“Sub”), UCG, Inc., a Florida corporation (“Seller”), SG 77 Inc., a Delaware corporation and wholly-owned subsidiary of Seller (“SG”), and RNA Ltd., an Israeli company and a wholly owned subsidiary of SG (“RNA”).RNA. Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”).Company. The Merger became effective as of April 29,27, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.

14

 

RNA is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is primarily engaged in the marketing and distribution of cybersecurity related products. In anticipation of the transaction contemplated under the Merger Agreement, SG was formed and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

Following the closing, each of SG 77 and RNA became wholly-owned subsidiaries of the Company.

 

17

Recent Developments

Acquisition of CrossMobnile

 

(i) As previously disclosed, WHEN completedOn March 22, 2022 the acquisition of a 26% equity interest inCompany, CrossMobile Sp.Sp z o.o,o.o., a company formed under the laws of Poland (“CrossMobile”). On March 22, 2022 the Company, CrossMobile and the shareholders of CrossMobile (of which our CEO, Giora Rosenzweig, holds 40.67% and George Baumeohl, a director, holds 6.67%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to purchasepurchased in July 2022 an initial 26% equity stake of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). Prior toIn addition, for 18 months following the closing, Mr. Giora Rozensweig, the Company CEO, held 40.67% and Mr. George Baumeohl, a director, held 3.33%,date of the issued preferred share capital of CrossMobile). The preferred share capital of CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile.

CrossMobile filed an application with the Polish Companies Registrar on June 22, 2022 to increase its share capital in order to effectuate the issuance to WHEN of the CrossMobile ordinary shares representing 26% of the CrossMobile equity interest to WHEN and to register the issuance to CrossMobile of the 10,000,000,000 WHEN shares in consideration thereof. The Companies Registrar approved the requested actions on July 22, 2022 and published on August 1, 2022. The approval and registration by the Polish Companies Registrar is required under local law for CrossMobil to issue to WHEN the CrossMobile ordinary shares representing 26% of CrossMobile. In anticipation of the approval of the increase in the share capital of CrossMobile, WHEN issued to CrossMobile on July 13, 2022 the 10,000,000,000 WHEN shares.

Through January 22, 2024,Agreement, the Company has the option to purchase additional shares of CrossMobile, (the “Additional Share Purchase Option”), such that following such additional purchase, the Company wouldshall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In the eventOn October 25, 2022, the Company electsexercised the Additional Share Purchase Option to exercise the option,acquire such additional shares of CrossMobile and the Company shall issue such numbernow holds approximately 51% of restrictedCrossMobile’s outstanding share capital on a fully diluted basis and proportionally voting rights. In consideration for the exercise of the Additional Share Purchase Option, the Company issued to CrossMobile an additional 10,000,000 shares of the Company’s common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.stock.

 

Following the closing of the Initial Investment, Ms. Gaya Rozensweig, a Company director, was appointed to the CrossMobile board of directors.

Following the Initial Investment, the combined holdings of Giora Rozensweig and WHEN, afford them effective control of the majority of the outstanding voting capital of CrossMobile

Business Overview

provides public mobile telephone services in Europe, (without its own radio infrastructure) We believe that the acquisition of CrossMobile provides an opportunity in our evolution and provides us with a strong foothold in the European market.mobile telecom market.. CrossMobile is partplanning to roll-out a comprehensive suite of a limited group of licensed mobile virtual network operators (MVNO)value-added services for B2B and B2C customers in the European Union.telecom industry.

With our involvement in CrossMobile, we expect to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

 

The global telecom services market size was valued at $1.6 trillionUSD 1,805.61 billion in 20202022 and is expected to growexpand at 5.4% Compound Annual Growth Ratea compound annual growth rate (CAGR) through 2028of 6.2% from 2023 to 2030 1. The global cybersecuritycyber security market was valued at $140size is projected to grow from $172.32 billion in 2021 and is expected2023 to reach $376$424.97 billion by 2029in 2030, at a CAGR of 13.8%2. By combining the telecom focus with our existing cyber security product offering, our plan is to bring to market a new standard of service in value added telecom and security solutions for B2B and B2C customers alike.

1 Global Telecom Services Market Size Report, 2021-2028. (2022). Retrieved 21 August 2022, from https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

2 Insights, F. (2022). With 13.4% CAGR, Global Cyber Security Market Size to Surpass USD 376.32 Billion in 2029. Retrieved 21 August 2022, from https://www.globenewswire.com/news-release/2022/06/14/2461786/0/en/With-13-4-CAGR-Global-Cyber-Security-Market-Size-to-Surpass-USD-376-32-Billion-in-2029.html

15

By combiningDuring the current solutions of these two divisions, WHEN expects to commercialize a new standard of service in value added telecom and security solutions for B2B and B2C customers alike.

Our strategic plan for the next 12six months includesended June 30, 2023, CrossMobile accomplished the following

 

a.Integrating IT infrastructure with MNO Telecom operator in Poland on standard packages of Voice, SMS and Data service. (name of Telekom operator will be released in separate announcement)
b.Finalizing tests of platform for sales and customer care. This platform will be based on in-house artificial intelligence systems to keep operating costs substantially below market
c.Start test of integration with and sales of Data packages

 

CrossMobile anticipates that it will be able to go live in December 2022 with the following:

a.Be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming.
b.Generate first invoice forCommence initial sales business customers of standard packages of Voice, SMS and Data in Poland and International Roaming that will generate first invoice in July 2023
c.Due to the need of focusing on sales, technical issues and corporate governance we postponed until Q3 to fully Initiate cooperation with existing or build new MVNO Telecom operators similar to CrossMobile to fully optimize ROI on the investment made in people and IT Systems. Focus areas will be USA, UK, Asia Pacific and selected countries in Europe with high potential.

Acquisition of Instaview

Key Financial Terms

On Feb. 26, 2023 we completed the acquisition of an initial 26% of Instaview Ltd. (“Instaview”), an emerging technology company in the field of AI-based image processing systems, thermal cameras, home and Metricsenterprise security, livestock tracking and control appliances plus much more.

Instaview is engaged in the field of image processing systems and thermal cameras. Over the past 18 years, Instview has provided innovative security and managing solutions in hundreds of projects in Israel and overseas.

We believe that there is synergy between Instaview and our activities and marks the beginning of the revolution of the home and enterprise security market, which is estimated to be $120 billion in 2022 and projected to grow at a compound annual growth rate of 8% through 2030.”

1 Grand View Research, from https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

2 https://www.fortunebusinessinsights.com/industry-reports/cyber-security-market-101165

18

Combined WHEN Product Offerings

Our product offerings are comprised of three complementary segments, namely

1.Cyber Care, which is the long standing and core business segment of WHEN
2.AI based image processing systems such as audio-video systems and security cameras solutions being an off-line extension of the on-line Cyber Care services entered through the acquisition of 26% shares in Instaview
3.Mobile telecom GSM which is a new business segment, linking the off and on line business segments entered through the recent acquisition of CrossMobile

All three are targeting commercial enterprises (B2B) and individual users (B2C).

Cyber Care

B2B Offerings—Our B2B Cybersecurity system software development and implementation program focuses on developing a threat management software that provides innovative solutions for the constantly evolving cyber challenges of businesses, non-governmental organizations (NGO’s) and governmental entities.

In 2021 we launched OTOGRAPH, our comprehensive cybersecurity and information security system, to enable business enterprises to monitor, analyze and prevent suspicious or harmful behavior on corporate networks and connected devices. The OTOGRAPH is designed to analyze and prevent internal or external abuse or abnormal activity on enterprise devices, such as PCs, mobile phones, servers or any other operating system (OS)-based Internet of things (IOT) devices. IoT devices are the nonstandard computing devices that connect wirelessly to a network and have the ability to transmit data.

 

The following discussion summarizesrapid transition to open and cloud-based remote workforce has exposed businesses and organizations across the key factors our management believes are necessary for an understandingworld to higher risks of our consolidated financial statements.cyber-attacks and information security breaches. To enable businesses to better protect their data and workflow, we developed a Business Behavioral Analysis (BBA) system that enables business leaders to track all activity from any given location on a one-stop dashboard. Developed over the past two years, OTOGRAPH provides aggregated data and a wide variety of real-time analytics such as real time monitoring of online behavior, applications and system behavior, data breaches, internal and external connections analytics, productivity analysis and psycholinguistic analysis. Corporations and organizations can then use the dashboard to detect suspicious human or device activities that put their company at risk.

 

RevenuesOTOGRAPH was developed based on based on a state of the art intelligence technology combined with AI technology that processes and analyzes massive amounts of behavioral and communication data and enables organizations to make real time accurate preventive assessments and decisions to protect company assets and ensure operational efficiency. OTOGRAPH deploys a unique Business Behavioral Analysis (BBA) machine learning software. Behavioral digital data is extracted from all endpoint devices that are connected to the company’s network infrastructure – whether physically, wirelessly or remotely. The data is processed and analyzed to learn and to reveal the unique digital behavioral pattern of the organization as a whole and of every endpoint or individual.

OTOGRAPH then sets baselines of normal patterns for each, and constantly searches for anomalies – deviations from those expected patterns. The anomalies are detected automatically and instantly, categorized by their type and generate push alerts which are sent to the business leader’s dashboard and enabling him to respond to the threat.

OTOGRAPH is continuously learning and calibrating the normal patterns and their thresholds to minimize the number of false alarms and constantly adapt to the changing needs of organizations in real time. Our B2C Cybersecurity division targets families concerned with external cyber threats and exposures in addition to monitoring a child’s behavioral patterns that may alert parents to potential tragedies caused by cyber bullying, pedophiles, other predators, and depression.

B2C

SG’s Parental System offers a comprehensive solution which is designed to enable parents wishing to observe their children’s online behavior to learn if they are accessing inappropriate websites and content and/or to protect them from a range of threats including cyberbullying, pedophiles and other predators and identity theft.

19

The Parental System line is positioned as the “ultimate parental cyber solution”. This system incorporates a range of features enabling parents to view and manage their children’s Android phones and devices. The key elements of our proprietary solutions include the following: analysis of all incoming and outgoing written data; analysis of all incoming and outgoing audio communication; real time location tracking; environmental surroundings analysis; and cyber activity analysis.

The Parental System has similar features to those of the B2B yet tailored to fit the needs of parents and guardians to protect their children. Such variations focus on online behavioral patterns whether vocally, via short message service (“SMS”) or social media platforms. If there is a change in behavior patterns, the product is designed to immediately send the parent or adult guardian an alert. For example, as stated in several international reports, one of the identifiable indicators before suicide is social withdrawal, something which today appears as a significant decrease in text message exchanges. The system categorizes this decrease as a red flag. Moreover, there are certain words and phrases which increase in use prior to suicide which the system will detect these it will put them in the red flag category.*

* https://www.mayoclinic.org/healthy-lifestyle/tween-and-teen-health/in-depth/teen-suicide/art-20044308

While analyzing voice calls based on; tone of speech, lengths of the conversation and the frequency of calls, Parental System Analytics is capable of identifying changes in behavioral patterns and flagging these changes. For example, studies showed that with deteriorating mental health, the frequency of calls decreases and the sentences along with the length of the conversations get shorter. Any such discrepancy in behavior patterns will send a real time alert to the parent or legal guardian, potentially avoiding a tragedy.

Strategy Cyber Care: We believe that the technology underlying our product offering is our primary competitive advantage. The strength of our solution is driven by several proprietary technologies and methodologies that we have developed, coupled with how we have combined them into our highly versatile platform incl. the mobile telecom platform discussed below. These advantages enable our end users to

Prevent trade secret and data leakage;
Protect against hackers;
Minimize loss of productivity;
Detect embezzlements and thefts;
Defend employees from harassments;
Prevent talent and client poaching;
Avoid human errors;
Develop a new level of decision-making ability based on accurate and real-time data; and
Assist parents and legal guardians in monitoring their minor children’s’ cyber online activities.

The Company’s go-to-market strategy focuses principally on generating revenue from software, services and licensing. The Company intends to drive revenue growth and to achieve margins that are consistent with those of other enterprise software companies.

 

We currently generate revenues primarilyintend to sell substantially all of our products and services to distributors and resellers, which will sell to end-user customers, which we refer to in this report as our customers.

The implementation of our strategies is subject to our raising significant cash resources, of which no assurance can be provided that we will be successful in raising the needed capital on commercially reasonable terms. As of the date of this prospectus, we have no commitments for any capital raise.

20

Mobile telecom GSM

Following the first step, our next planned strategy is to add the advanced B2B and B2B Cyber Care bundled with the audio-video systems and security cameras solution and offer them as an integrated part of our GSM solutions. This will give our B2B the possibility to use the AI and BBA as a tool to increase not only security but as well efficiency in sales organizations where soft skills, emotions and personal relations are crucial.

In respect to the B2C market our strategy is to give families a tool to protect their assets and entire households in particular kids or pets and evenelderly members being fragile newcomers in the world of e-commerce, on-line banking and on-line dating.

The third step expected to be initiated in Q3 2023 in is to copy and paste the same scenario of combining Cyber Care and Mobile Telecom to other selected markets in North Africa, the USA and Europe.

To execute this strategy CrossMobile has engaged with not only telecom industry experts but as well high level sales experts from software license fees.international FMCG sector that is expected to bring a new standard of cross selling and customer experience to the telecom market

Comparison of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022

Summary of Results of Operations

  Three months ended 
  June 30 
  2023  2022 
       
Revenues $102,646   11,212 
Operating Expenses        
Research and development expenses  (502,187)  (327,838)
Selling and marketing expenses  (3,527)  - 
General and administrative expenses  (1,148,382)  (2,458,216)
Operating loss  (1,551,450)  (2,774,842)
Financing income, net  10,614   33,338 
Loss before equity in net loss of equity investments  (1,540,836)  (2,741,504)
Less: Equity in net loss of equity investments  250   - 
Net loss  (1,540,586)  (2,741,504)
Net loss attributable to non-controlling interests  12,930   - 
Net loss attributable to the Company’s stockholders  (1,527,656)  (2,741,504)

Revenues

Our total revenue consists of sales of our products and services.

Operating Expenses

Our current operating expenses consist of three components - research and development expenses, selling and marketing expenses and general and administrative expenses.

 

Research and Development Expenses, net

 

The process of researching and developing our product candidates is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses through 2023for the next several years as we continue to develop our product offerings and adapt them to our new MVNO business.lines. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred..incurred. The design and development activities will consume a large proportion of our current, as well as projected, resources.

21

Our research and development costs include costs are comprised of:

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

The following table discloses the breakdown of research and development expenses:

  Three Months Ended
June 30
 
  2023  2022 
Salaries and related expenses $111,339   88,022 
Share-based compensation expenses  349,867   208,321 
Subcontractors and other development costs  5,887   7,251 
Depreciation and amortization  4,305   9,970 
Rent and office maintenance  24,465   1,870 
Other expenses  6,324   12,405 
Total $502,187   327,838 

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related expenses, professional services and other expenses.

The following table discloses the breakdown of selling and marketing expenses:

  Three Months Ended
June 30
 
  2023  2022 
Professional services  3,527   - 
Total $3,527   - 

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts in 2023 following the acquisition of Cross Mobile and our efforts to be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming and initiate cooperation with existing or build new Telecom operators.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses, professional services, rent and office maintenance and other non-personnel related expenses.

22

The following table discloses the breakdown of general and administrative expenses:

  Three Months Ended June 30 
  2023  2022 
Salaries and related expenses $55,477   63,089 
Share-based compensation expenses  975,319   2,310,512 
Professional services  86,067   30,357 
Rent and office maintenance  16,346   30,153 
Other expenses  15,173   24,105 
Total $1,148,382   2,458,216 

Revenues

Revenues for the three months ended June 30, 2023 and 2022 were $102,646 and $11,212, respectively. The increase in our revenues resulted primarily from services provided under a development agreement in an amount of $90,000 recognized during the three months ended June 30, 2023.

Research and Development Expenses. Research and development expenses consist of salaries and related expenses, share-based compensation expenses, consulting fees, service providers’ costs and overhead expenses. Research and development expenses increased from $327,838 during the three months ended June 30, 2022 to $502,187 during the three months ended June 30, 2023. The increase resulted primarily from increase in non-cash share-based compensation expenses, salaries and related expenses and in rent and maintenance costs partially offset by decrease in and depreciation costs associated with our development activities.

Selling and Marketing Expenses. Selling and marketing expenses consist primarily of professional fees. Selling and marketing expenses for the three months ended June 30, 2023 amounted to $3,527 as compared to $0 for the three months ended June 30, 2022. The increase is primarily attributable to expenses incurred in connection with the purchase of 51% of CrossMobile, which we completed in November 2022.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses, share-based compensation expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses decreased from $2,458,216 for the three months ended June 30, 2022 to $1,148,382 in the three months ended June 30, 2023. The decrease is primarily attributed to the decrease in non-cash share-based compensation expenses partially offset by increase in professional services.

Financing Income, Net. Financing income, net decreased from $33,338 of financing income for the three months ended June 30, 2022 to financing income, net of $10,614 for the three months ended June 30, 2023. The decrease is mainly a result of currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. As a result of the foregoing, our net loss for the three months ended June 30, 2023 was $1,540,586 compared to $2,741,504 for the three months ended June 30, 2022.

Comparison of the six Months Ended June 30, 2023 to the six Months Ended June 30, 2022

Summary of Results of Operations

  Six months ended 
  June 30 
  2023  2022 
       
Revenues $134,986   43,754 
Operating Expenses        
Research and development expenses  (1,005,123)  (451,344)
Selling and marketing expenses  (30,197)  - 
General and administrative expenses  (3,132,840)  (4,007,344)
Operating loss  (4,033,174)  (4,414,934)
Financing income, net  15,503   36,634 
Loss before equity in net loss of equity investments  (4,017,671)  (4,378,300)
Less: Equity in net loss of equity investments  (227)  - 
Net loss  (4,017,898)  (4,378,300)
Net loss attributable to non-controlling interests  25,942   - 
Net loss attributable to the Company’s stockholders  (3,991,956)  (4,378,300)

23

Revenues

Our total revenue consists of sales of our products and services.

Operating Expenses

Our current operating expenses consist of three components - research and development expenses, selling and marketing expenses and general and administrative expenses.

Research and Development Expenses, net

We expect to continue incurring substantial expenses for the next several years as we continue to develop our product lines. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. The design and development activities will consume a large proportion of our current, as well as projected, resources.

 

Our research and development costs include costs are comprised of:

 

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

 

● fees paid to external parties who provide us with contract services.services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

 

The following table discloses the breakdown of research and development expenses:

  Six Months Ended
June 30
 
  2023  2022 
Salaries and related expenses $173,683   176,099 
Share-based compensation expenses  750,391   208,321 
Subcontractors and other development costs  14,719   17,200 
Depreciation and amortization  8,573   23,945 
Rent and office maintenance  47,089   19,384 
Other expenses  10,667   6,395 
Total $1,005,123   451,344 

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related expenses, professional services and other expenses.

The following table discloses the breakdown of selling and marketing expenses:

  Six Months Ended
June 30
 
  2023  2022 
Professional services  30,197   - 
Total $30,197   - 

1624

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts in 2023 following the acquisition of Cross Mobile and our efforts to be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming and initiate cooperation with existing or build new Telecom operators.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries employee benefits, equity compensation,and related expenses, professional services, rent and office maintenance and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.

Financial Expenses

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank’s fees and interest on long term loans.

Comparison of the Three Months Ended June 30, 2022 to the Three Months Ended June 30, 2021non-personnel related expenses.

 

The following table presentsdiscloses the breakdown of general and administrative expenses:

  

Six Months

Ended June 30

 
  2023  2022 
Salaries and related expenses $149,916   129,049 
Share-based compensation expenses  2,821,682   3,737,003 
Professional services  106,409   57,134 
Rent and office maintenance  47,200   46,473 
Other expenses  7,633   37,685 
Total $3,132,840   4,007,344 

Revenues

Revenues for the six months ended June 30, 2023 and 2022 were $134,986 and $43,754, respectively. The increase in our resultsrevenues resulted primarily from services provided under a development agreement in an amount of operations for$90,000 recognized during the three months ended June 30, 2022 and 20212023.

  Three Months Ended 
  June 30 
  2022  2021 
       
Revenues  11,212   48,801 
Operating Expenses        
Research and development expenses  (119,518)  (81,089)
General and administrative expenses  

(147,704

)  

(145,169

)
Share based compensation expenses  (2,518,832)  -
Operating loss  (2,774,842)  (177,457)
Financing income (expenses), net  33,338   (29,432)
Net loss  (2,741,504)  (206,889)

 

Revenues. Revenues for the three months ended June 30, 2022 and 2021 were $11,212 and $48,801, respectively. Revenues were comprised primarily of software license fees. The decrease in revenues is primarily related to efforts we undertook in the 2022 period to refocus our resources on the CrossMobile transaction.

Research and Development. Development Expenses. Research and development expenses consist of share based compensation, salaries and related expenses, share-based compensation expenses, consulting fees, service providers’ costs related materials and overhead expenses. Research and development expenses increaseincreased from $81,089 in$451,344 during the threesix months ended June 30, 20212022 to $119,518$1,005,123 during the corresponding period in 2022.six months ended June 30, 2023. The increase resulted primarily from share basedincrease in non-cash share-based compensation expenses.

and in rent and maintenance costs partially offset by decrease in salaries and related expenses and depreciation costs associated with our development activities.

 

Selling and Marketing Expenses. Selling and marketing expenses consist primarily of professional fees. Selling and marketing expenses for the six months ended June 30, 2023 amounted to $30,197 as compared to $0 for the six months ended June 30, 2022. The increase is primarily attributable to expenses incurred in connection with the purchase of 51% of CrossMobile, which we completed in November 2022.

General and Administrative Expenses. Expenses. General and administrative expenses consist primarily of salaries and related expenses, share-based compensation expenses and other non-personnel related.related expenses such as legal expenses. General and administrative expenses increaseddecreased from $145,169$4,007,344 for the threesix months ended June 30, 20212022 to $147,704 during$3,132,840 in the corresponding periodsix months ended June 30, 2023. The decrease is primarily attributed to the increase in 2022.non-cash share-based compensation expenses partially offset by increase in professional services, salaries and related expenses and other non-personnel related expenses.

 

Financing Expenses, Net. Income, Net. Financing expenses,income, net decreased from $36,634 of financing for the threesix months ended June 30, 2021 amounted2022 to $29,432. Financingfinancing income, net of $15,503 for the threesix months ended June 30,, 2022 amounted to $33,338. 2023. The increasedecrease is mainly due toa result of currency exchange differences between the Dollar and the New Israeli Shekel.

 

Net Loss. Net loss for the three months ended June 30, 2022 was $2,741,504 and is primarily attributable to non-cash share based compensation expense of $2,310,512, research and development and general and administrative expenses.

17

ComparisonAs a result of the Six Months Ended June 30, 2022 to the Six Months Ended June 30, 2021

The following table presentsforegoing, our results of operations for the three months ended June 30 2022 and 2021

  Six Months Ended 
  June 30 
  2021  2020 
       
Revenues  43,754   81,450 
Operating Expenses        
Research and development expenses  (243,024)  (253,860)
General and administrative expenses  

(270,341

)  

(269,654

)

Share based compensation expenses

  

(3,945,323

)  -
Operating loss  (4,414,934)  (442,064)
Financing income (expenses), net  36,634   (30,916)
Net loss  (4,378,300)  (472,980)

Revenues. Revenues for the six months ended June 30, 2022 and 2021 were $43,754 and $81,450, respectively. Revenues were comprised primarily of software license fees. The decrease in revenues is primarily related to efforts we undertook in the 2022 period to refocus our resources on the CrossMobile transaction

Research and Development. Research and development expenses consist of share based compensation, salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses increased from $253,860 for the six months ended June 30, 2021 as compared to $243,024 during the corresponding period in 2022. The increase resulted primarily from increase in share based compensation expenses.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses increased from $269,654 for the six months ended June 30, 2021 as compared to $270,341 in 2022 during the corresponding period in 2022.

Financing Expenses, Net. Financing expenses, net for the six months ended June 30, 2021 amounted to $30,916. Financing income, net for the six months ended June 30, 2022 amounted to $ 36,634. The increase is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. Net loss for the six months ended June 30, 20222023 was $4,017,898 compared to $4,378,300 and is primarily attributable to non-cash share based compensation expense of $3,737,003, research and development and general and administrative expenses.for the six months ended June 30, 2022.

25

Financial Condition, Liquidity and Capital Resources

 

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At June 30, 2023 and December 31, 2022, and 2021, we had current assets of $1,496,376$448,604 and $124,056$276,508, respectively, and total assets of $1,752,336$10,535,50 and $401,287$10,233,018 respectively. The increase in total assets is primarilymainly due to anthe increase in our cash balance, payments on accountintangible assets attributable to the purchase of investment26% of the issued and prepaid share based payment to service providers balance.outstanding shares of InstaView. We had current liabilities of $723,498$664,641 as compared to $557,613$787,683 as of June 30, 20222023 and 2021,December 31, 2022, respectively and total liabilities of $3,020,526$3,815,403 as compared to $2,856, 829$3,948,646 as of June 30, 2023 and December 31, 2022, and 2021, respectively. The increase is mainly attributed to the increase in the balance of employees and related institutions, accrued expenses, and increase in loans received from a related party offset by decrease in right of use liabilities arising from operating lease.

18

 

At June 30, 2022,2023, we had a cash balance of $407,979$267,151 compared to the cash balance of $46,022$56,346 as of December 31, 2021.2022. We have no cash equivalents.

 

At June 30, 2022,2023, we had a negative working capital of $772,878$216,037 as compared with a working capital deficiency of $547,972$511,175 at December 31, 2021.2022.

 

In JanuaryNovember 2022, the Company received $34,000 from an investor whowe entered into a subscriptionan investment agreement with the Company in October 2021 forGeorge Baumeohl, our director, pursuant to which Mr. Baumeohl has agreed to support our operation by way of an equity investment of $200,000up to be remitted$3 million through August 2025, as needed. The agreement provides for sales of our common stock to the CompanyMr. Baumeohl at per share purchase prices ranging between $0.0003 and $0.0005. Through June 30, 2023, we have received an aggregate of $625,000 from Mr. Baumeohl in periodic three month instalments, representing the second agreed upon instalment amount. In accordance with the termsrespect of his subscription agreement,which we issued to the investor a total 340,000,000him in May and June 2023 2,083,333,333 shares of our common stock and he is entitled to warrants for an additional 680,000,000 sharesat a share price of our common stock. In May 2022, we received $40,000 from the same investor, representing the third agreed upon instalment amount to be remitted to the Company. In accordance with the terms of his subscription agreement, we issued to the designees of such investor a total 400,000,000 shares of our common stock and he is entitled to warrants for an additional 800,000,000 shares of our common stock.$0.0003.

 

During March 2022,In addition, in February 2023, the Company issued to an investor and certain investors entered into subscription agreements for a private placementdesignee an aggregate of units1,440,000,000 shares of common stock in satisfaction of a loan made by the investor to the Company securities in an aggregatedthe principal amount of $500,000, where each unit (a “Unit” and collectively$120,000 plus interest of $24,000 of accrued interest for the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. In consideration thereof the holders are entitled to 5,000,000,000 shares of Common Stock and warrants for an additional 5,000,000,000 shares of Common Stock, of which to date 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock have been issued.10-year loan period.

 

During May 2022,Management believes that funds on hand, as well as the Company entered intosubscription proceeds that we are to receive on a periodic basis under the committed subscription agreements with two investors for a private placement of units of the Company securities in an aggregated amount of $250,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) two common stock purchase warrants to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0003. The price per unit was $0.0003. In consideration thereof the holders are entitled to 833,333,334 shares of Common Stock and warrants for an additional 1,666,666,668 shares of Common Stock, of which to date the shares of Common Stock and warrants have been issued.

We expect that our existing cash and cash equivalents as well as expected periodic remittances from subscription proceedsdirector, will enable us to fund our operations and capital expenditure requirements through March 2023.the next twelve months. Our requirements for additional capital during this period will depend on many factors, including the amounts necessary to bring the CrossMobile operations live by December 2022.factors.

 

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidatesc,andidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

19

Going ConcernCritical Accounting Policies

 

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. We have a stockholders’ deficitin conformity with accounting principles generally accepted in the United States of $1,268,160 and a working capital of $772,878 at June 30, 2022 as well as negative operating cash flows. These conditions raise substantial doubt about our ability to continue as a going concern. TheAmerica (“GAAP”). In preparing the consolidated financial statements, do not include any adjustmentsmanagement is required to make estimates and assumptions that might be necessary ifaffect the reported amounts of assets and liabilities as of the date of the consolidated balance sheets and consolidated statements of operations. Actual results may differ significantly from those estimates.

26

While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K we believe that the following accounting policies are unablethose most critical to continue as a going concern.the judgments and estimates used in the preparation of our consolidated financial statements.

 

Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.stockholders.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2022.2023. Based on that evaluation, our management, including our Interim Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of June 30, 2022.2023.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2021,2022, our management concluded that our internal control over financial reporting was not effective at December 31, 2021.2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The limitation of the Company’s internal control over financial reporting was due to the applied risk-based approach which is indicative of many small companies with limited number of staff in corporate functions. The identified weakness were:

 

Material Weakness – We did not maintain effective controls over certain aspects of the financial reporting process because we (i) lacked a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and (ii) we lacked controls over the disclosure of our business operations.
  
lack of segregation of duties Significant Deficiencies – Inadequate segregation of duties.

 

Our management believes the weaknesses identified above have not had any material effect on our financial results.

 

We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP and establish an audit committee and implement internal controls and procedures, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements.

 

2027

Changes in Internal Controls over Financial Reporting.

 

Except for the material weakness and associated remediation plan, ,noted above, there have been no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 20222023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The Suit soughtsuit seeks declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

 

A hearing was set for January 6, 2021 whereupon mediation was ordered. Mediation meetings were held but no resolution was reached. The Florida lawsuit is currently pending.

 

On or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained the services of Delaware counsel and has moved to dismiss or stay the 2022 Lawsuit in favor of the previously filed Florida lawsuit, which involves the same parties and same issues. The Company’s motion is currently pending in the Delaware Court of Chancery.

 

On June 24, 2022 the Company filed an amended complaint in Palm Beach County, Florida (CASE NO. 50-2020- CA-011735), alleging violation of Fla. Stat. 517.301, seeking declaratory relief with regard to the status of the shares held and transferred by EL, and seeking a temporary injunction with regard to the transfer of any subject shares. EL answered the complaint and a hearing has been set for September 12, 2023.

 

The Company intends to continue to vigorously pursue this action and avail itself of all options lawfully available to it.

 

From time to time, we may become involved in various lawsuits and legal proceedings thatwhich arise in the ordinary course of business, including actions relatedbusiness. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, webusiness. We are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.against us.

 

ITEM 1A. RISK FACTORS

 

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021,2022, as filed with the SEC on April 14, 2022,17, 2023, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2021.2022.

28

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

(i) In January 2022,On May 15, 2023, the Company received approximately $34,000 from an investor who entered into a subscription agreement with the Company in October 2021for an investment of $200,000, representing the second agreed upon periodic instalment. In accordance with the terms of his subscription agreement, we issued to the such investor in February 2022 a total 340,000,000770,000,000 shares of our common stock and the investor is entitled to warrants for an additional 680,000,000.as consideration under InstaView Transaction.

 

(ii) DuringIn May 2022,2023, the Company and two investors entered intoreceived subscription agreements for a private placementproceeds of units$150,000 under the investment agreement with Mr. Baumeohll in respect of which in respect of which in respect of which in May 2023 the Company securitiesissued in an aggregated amount of $250,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) two common stock purchase warrantsMay 2023 to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0003. The price per unit was $0.0003. In consideration thereof the holders are entitled to 833,333,334Mr. Baumeohl 500,000,000 shares of Common Stock and warrants for an additional 1,666,666,668 shares of Common Stock, of which to date the shares of Common Stock and warrants have been issued.Stock.[ David – I don’t get this one? Why not 1,583,333,333]

21

 

(iii) In May 2022,June 2023, the Company received $40,000 from subscription proceeds of $150,000 under the investor referred to in (i) above who entered into a subscriptioninvestment agreement with the CompanyMr. Baumeohll in October 2021for an investmentrespect of $200,000, representing the third agreed upon instalment amount to be remitted to the Company. In accordance with the termswhich in respect of his subscription agreement, we issued to the designeeswhich in respect of such investor a total 400,000,000 shares of our common stock and he is entitled to warrants for an additional 800,000,000.

(iv) Inwhich in May 2022, the Company awarded to employees and service providers, including the CEO, options under the Company’s 2021 Equity Incentive Plan to purchase 34,900,000,000  shares of the Company’s common stock, at a per share exercise price of $0.0001 per share, which the exercise price vest as follows: 25% (i.e., 1,500,000,000) option shares vest on the first anniversary of the grant date and the balance in increments of 400,000,000 shares on each subsequent three (3) month anniversary. Of the Options granted, the CEO received options for 5,000,000 shares.

(v) In May 2022, in consideration of legal services provided,2023 the Company issued in May 2023 to a consultant 30 millionMr. Baumeohl 500,000,000 shares of the Company’s common stock.Common Stock

 

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION:

 

None

 

ITEM 6. EXHIBITS

 

Exhibit Index:

 

10.1

Investment Agreement dated as of March 22, 2022 among the Company, CrossMobile and the CrossMobile shareholders

31.1* Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
   
32.1* Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS Inline XBRL Instance Document
   
101.SCH Inline XBRL Taxonomy Extension Schema
   
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase
   
101.LAB Inline XBRL Taxonomy Extension Label Linkbase
   
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

2229

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

WORLD HEALTH ENERGY HOLDINGS, INC. 
(Registrant) 
   
By:/s/ Giora Rozensweig 
 Giora Rozensweig 
 Interim Chief Executive Officer 
 (Principal Executive Officer and Principal Financial and Accounting Officer) 
   
Date:August 22, 202214, 2023 

 

2330